454 Life Sciences and GenomeQuest Team Up to Provide Next-Generation Sequence Search and Analysis Services
News Oct 03, 2008
454 Life Sciences, a Roche company, and GenomeQuest, Inc. announced a co-marketing agreement whereby GenomeQuest will offer its recently launched On-Demand Informatics Service to users of the 454 Genome Sequencer FLX System.
GenomeQuest’s high-throughput annotation and data management tools enable characterization of all sequences generated by the Genome Sequencer FLX System.
The combination of the Genome Sequencer FLX System’s comprehensive sequence results and GenomeQuest’s informatics tools increase both speed and convenience in converting the increasing volume of sequence data into biologically meaningful information.
“With over 250 peer-reviewed publications utilizing 454 Sequencing, our customers enjoy the benefit of sophisticated bioinformatics solutions,” says Chris McLeod, CEO of 454 Life Sciences, a Roche company.
“Our system’s long reads and analysis tools provide rapid de novo assemblies of complex genomes. Offering complementary bioinformatics tools enhances our customers’ ability to quickly extract biological meaning from their experiments. GenomeQuest has proven that their annotation solutions are capable of delighting our customers.”
The co-marketing agreement resulted from extensive pilot activities conducted to evaluate the scientific accuracy and scalability of GenomeQuest’s algorithms and informatics platform. The goal was to assess the value that GenomeQuest could provide Genome Sequencer FLX System users.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.